TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Consensus Rating of “Buy” from Analysts

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has earned a consensus recommendation of “Buy” from the eight ratings firms that are covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $12.08.

A number of analysts have recently issued reports on the company. Oppenheimer began coverage on TriSalus Life Sciences in a research note on Monday, September 16th. They issued an “outperform” rating and a $10.00 price target on the stock. Northland Securities began coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 price objective on the stock. Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Roth Mkm began coverage on TriSalus Life Sciences in a research note on Monday, November 11th. They set a “buy” rating and a $11.00 price objective on the stock. Finally, Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th.

TriSalus Life Sciences Price Performance

TriSalus Life Sciences stock opened at $4.12 on Wednesday. The stock has a market capitalization of $125.62 million, a PE ratio of -1.65 and a beta of 0.49. TriSalus Life Sciences has a 12 month low of $3.32 and a 12 month high of $10.42. The business has a 50 day simple moving average of $4.29 and a 200-day simple moving average of $5.68.

Insiders Place Their Bets

In other TriSalus Life Sciences news, CEO Mary T. Szela bought 7,520 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was acquired at an average cost of $5.20 per share, with a total value of $39,104.00. Following the purchase, the chief executive officer now owns 377,382 shares in the company, valued at approximately $1,962,386.40. This represents a 2.03 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 32.80% of the stock is owned by insiders.

Hedge Funds Weigh In On TriSalus Life Sciences

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC increased its position in TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after buying an additional 62,542 shares in the last quarter. Vestcor Inc purchased a new position in TriSalus Life Sciences during the third quarter worth $108,000. MSD Partners L.P. purchased a new position in TriSalus Life Sciences during the third quarter worth $184,000. Walleye Capital LLC purchased a new position in TriSalus Life Sciences during the third quarter worth $66,000. Finally, Duquesne Family Office LLC increased its position in TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after buying an additional 110,966 shares in the last quarter. 2.58% of the stock is owned by hedge funds and other institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.